Not a gestapo policy. Harm reduction in the context of human frailty.

OPIOID STEWARDSHIP

This page exists because a regenerative medicine practice that says nothing about opioids is dodging the central question its patients are living with.

The position

For irreversible pain, the goal is not zero opioids. It is the minimum effective exposure with function preserved and harm prevented. That is harm reduction in the context of human frailty, not an abstinence policy, and it is not enforcement.

Two failures are possible here, not one. Careless prescribing has done enormous damage. So has the reaction to it — patients tapered abruptly by clinicians protecting themselves, people with real irreversible pain treated as suspects, and the predictable result of pushing someone off a cliff they were standing near. Untreated severe pain has its own mortality. Both failures are real, and pretending only one exists is how people get hurt.

How that shapes what happens here

• We do not require you to come off opioids to be treated.
• We do not treat a dose as a character judgment.
• Where an interventional or regenerative option can widen the window in which you can move, sleep and work, we attempt that than escalate a dose.
• Where it cannot, we say so rather than sell you a series of injections.

Why the metabolic work belongs in this conversation

The aim of the behavioral and metabolic side of the protocol is not virtue. It is retraining a nervous system to rely on its own endogenous endorphins rather than exogenous opioids — which requires sleep architecture that works, inflammatory load that is falling rather than rising, and enough restored function that movement is possible. Isolation and financial pressure work directly against all three, which is why they get asked about here rather than treated as background noise.

This is not a substitute for addiction treatment where that is what is needed, and we will say so directly if it is.

What the phrase has come to mean, and what it means here

“Stewardship” has been used to describe policies that amount to enforcement: mandatory tapers, dose ceilings applied without reference to the individual, patients discharged for a single irregularity. That is not what is meant here. In the words this practice actually uses, it is not a gestapo policy — harm reduction in the context of human frailty.

The distinction is practical rather than rhetorical. A policy aimed at reducing a number produces patients who conceal what they take, obtain it elsewhere, or are abandoned at the point they are least able to cope. A practice aimed at restoring function produces the dose conversation as a consequence, usually without an argument.

The two failures, held at the same time

Careless prescribing caused enormous harm, and that is not in dispute. What is less often said is that the correction caused harm of its own: abrupt tapers driven by clinicians protecting themselves, people with irreversible pain treated as suspects, and a well-documented rise in crisis among patients discontinued involuntarily.

Untreated severe pain has its own mortality — through cardiovascular strain, through immobility and its metabolic consequences, and through suicide. A position that acknowledges only one of these two failures is not a clinical position. It is a reputational one.

Why function is the target rather than the number

The reasoning is physiological rather than moral. The aim is to retrain a nervous system to rely on its own endogenous endorphins instead of exogenous opioids, and that requires three things a person in constant pain usually does not have.

• Sleep architecture that works. Most tissue repair signaling is nocturnal, and fragmented sleep raises inflammatory tone and lowers pain threshold. Opioids themselves disrupt sleep architecture, which is part of the trap.
• Falling rather than rising inflammatory load. Chronic metabolic inflammation amplifies nociceptive signaling. Immobility raises it; movement lowers it.
• Enough restored function that movement is possible at all. This is what an interventional or regenerative treatment can legitimately provide — a window.

Isolation and financial pressure work directly against all three, which is why they get asked about here rather than treated as background. Someone working double shifts to cover rent, sleeping five hours, with no one to help them, is not going to out-discipline that situation with a taper schedule.

What we will not do

• Require a taper as a condition of treating you.
• Treat your current dose as a character question.
• Discharge you for being honest with us.
• Pretend a regenerative treatment will fix something it will not, because it sounds better than saying we cannot help.
• Target advertising at opioid-seeking intent, which is a thing this field does and which this practice does not.

Where this practice draws a real line

Where the problem is an opioid use disorder rather than a pain problem being managed with opioids, that needs addiction treatment and we will say so directly. Those are different conditions with different treatments, and blurring them helps nobody. Dr. Padda is an addiction medicine specialist, so this is a distinction made from inside the field rather than at arm’s length from it.

Saying it plainly is part of the point: a patient who suspects they are being quietly assessed for a diagnosis nobody will name is not going to tell you the truth about anything.

Related reading

• Injury and work comp
• Still in pain after back surgery
• How PRP works
• Am I a candidate?
• About Dr. Padda
• Information for referring physicians

What a first appointment looks like if you are on opioids

Bring the actual list, including doses. Nobody is going to react to it, and an accurate picture is the only thing that makes the rest of the conversation useful.

We will want to know what the medication is doing for you in functional terms — what you can do on it that you could not do without it — because that is the measure that matters and it is rarely the one recorded. We will want to know about sleep, because opioids fragment it and fragmented sleep amplifies pain, and that loop is often more tractable than the dose.

If a regenerative option is a reasonable bet for your problem, we will say so and treat it. If it is not, we will say that instead of taking your money, and we will still try to be useful about what else might help.

Common questions

Will you make me taper before treating me?

No. That is not a condition of care here. How we assess candidacy.

Do you prescribe opioids?

This is a pain practice and prescribing is part of it, within the position described above. Contact us.

What if I think I have a problem with them?

Say so. It changes the plan toward treatment rather than judgment. About Dr. Padda.

Can PRP get me off pain medication?

Sometimes it widens the window enough that the question answers itself. It is not a promise. How PRP works.

Why a regenerative clinic writes this page at all

Most clinics selling PRP say nothing about opioids, and the omission is commercially sensible: it is a subject that attracts scrutiny and complicated patients. The reason it appears here is that the people most likely to arrive asking about regenerative treatment are frequently the same people who have been managed for years on escalating analgesia and told there is nothing further to offer.

That group is vulnerable to exactly the kind of overselling this field produces. Saying plainly what a treatment can and cannot do, to someone in that position, is a stewardship act in itself — because the worst outcome is not that a treatment fails. It is that someone spends what they have, concludes that everything has now been tried, and returns to a rising dose as the only remaining option.

Why the dose was ever the whole conversation

Symptom-based silos are the reason. Pain goes to one specialty, the blood sugar to another, the sleep to nobody, and the weight to a lecture. Each silo optimizes its own variable, no one owns the collision, and the only tool that spans all of them is a prescription.

That is medicalization doing what it does: milking the cow rather than curing the cow. It is not a claim that anyone acted badly. It is a description of what a system built on fifteen-minute encounters and procedure codes will reliably produce.

The neurobiology nobody explained to you

Chronic exogenous opioid exposure recalibrates dopaminergic drive. The receptor system that once responded to a meal, a walk, a conversation gets reset to a higher baseline, and everything below that line stops registering. This is the hedonic treadmill, and it is why the dose that worked in March does less in September without anyone doing anything wrong.

It also explains why subtraction alone fails. Take the drug away and you have not restored the reward system; you have removed the only thing still reaching it. The work that actually helps is hedonic substitution — rebuilding the endogenous signals that movement, sleep, food timing and human contact produce, so there is something on the other side of the taper besides absence.

That is the physiological argument for why lifestyle work is 40 to 50 percent of the protocol here rather than advice at discharge. It is not encouragement. It is the replacement signal.

The enemy in this story

Not the patient, and not the physician who prescribed in good faith under guidance that later reversed. The enemy is a set of incentives: a food supply engineered against dopamine circuitry, a payment system that funds the injection and not the hour of behavioral work, and an isolation epidemic that nobody codes for.

Loneliness belongs on that list and is usually left off it. Social disconnection raises inflammatory markers and lowers pain thresholds through mechanisms as measurable as any drug effect. A person in pain who is also alone is not experiencing two separate problems.

What the numbers look like where this is practiced

Dr. Padda’s interventional practice published its own opioid figures on International Overdose Awareness Day, August 31, 2026: the average new patient arrives after more than two and a half years in pain and above 90 morphine milligram equivalents a day; 21% are completely off opioid pain medication within 90 days of active interventional treatment and 34% within one year; and of those who cannot be fully weaned, the large majority are brought below 30 MME per day. These are practice-reported figures from that population, not trial outcomes, and individual results vary.

The point of publishing them is the mechanism rather than the arithmetic. A taper reduces a dose; treating the structure that is generating the pain changes why the dose was there. Read the release on AP News or in the original announcement.